JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morisset, S.
Right arrow Articles by Arrang, J.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morisset, S.
Right arrow Articles by Arrang, J.-M.

Vol. 300, Issue 2, 621-628, February 2002

Acute and Chronic Effects of Methamphetamine on Tele-Methylhistamine Levels in Mouse Brain: Selective Involvement of the D2 and not D3 Receptor

S. Morisset, C. Pilon, J. Tardivel-Lacombe, D. Weinstein, W. Rostene, C. Betancur, P. Sokoloff, J.-C. Schwartz and J.-M. Arrang

Unité de Neurobiologie et Pharmacologie Moléculaire (U109) de l'Institut National de la Santé et de la Recherche Médicale, Centre Paul Broca, Paris, France (S.M., C.P., J.T.-L., D.W., P.S., J.-C.S., J.-M.A.); and Imagerie Cellulaire des Neurorécepteurs et Physiopathologie Neuroendocrinienne, Hôpital Saint-Antoine, Paris, France (W.R., C.B.)

We have explored the role of endogenous dopamine in the control of histaminergic neuron activity in mouse brain regions evaluated by changes in tele-methylhistamine (t-MeHA) levels. In vitro, methamphetamine released [3H]noradrenaline but failed to release [3H]histamine from synaptosomes. In vivo, methamphetamine enhanced t-MeHA levels by about 2-fold with ED50 values of ~1 mg/kg in caudate putamen, nucleus accumbens, cerebral cortex, and hypothalamus. This response selectively involved the D2 and not the D3 receptor as indicated by its blockade by haloperidol and by its persistence after administration of nafadotride, a D3 receptor preferential ligand, or in (-/-) D3 receptor-deficient mice. The t-MeHA response to methamphetamine was delayed compared with the locomotor-activating effect of this drug, suggesting that it is of compensatory nature. In agreement, ciproxifan, an inverse agonist known to enhance histamine neuron activity, decreased the hyperlocomotion induced by methamphetamine. Repeated methamphetamine administration resulted in the expected sensitization to the hyperlocomotor effect of the drug but did not modify either the ED50 or the Emax regarding t-MeHA levels. However, it resulted in an enhanced basal t-MeHA level (+30-40%), which was sustained for at least 11 days after withdrawal in hypothalamus, striatum, and cerebral cortex and suppressed by haloperidol. Hence, both the acute and chronic administration of methamphetamine enhance histamine neuron activity, presumably in a compensatory manner. Repeated methamphetamine administration also resulted in a modified balance in the opposite influences of dopamine and serotonin on histaminergic neurons as revealed by the enhanced response to haloperidol and abolished response to ketanserin, respectively.


0022-3565/02/3002-0621$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
M. J. Millan, F. Loiseau, A. Dekeyne, A. Gobert, G. Flik, T. I. Cremers, J.-M. Rivet, D. Sicard, R. Billiras, and M. Brocco
S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side Effects
J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1212 - 1226.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
T. A. Esbenshade, G. B. Fox, and M. D. Cowart
Histamine h3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders.
Mol. Interv., April 1, 2006; 6(2): 77 - 88.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
C. Pillot, J. Ortiz, A. Heron, S. Ridray, J.-C. Schwartz, and J.-M. Arrang
Ciproxifan, a Histamine H3-Receptor Antagonist/Inverse Agonist, Potentiates Neurochemical and Behavioral Effects of Haloperidol in the Rat
J. Neurosci., August 15, 2002; 22(16): 7272 - 7280.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.